Page last updated: 2024-11-07

cp 55244

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

CP 55244: RN given refers to the (2alpha,4abeta,6alpha,8alpha,8aalpha)-(+-)-isomer; RN for cpd without isomeric designation not avail 9/90; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9844074
MeSH IDM0179771

Synonyms (16)

Synonym
cp 55244
cp 55,244
(2r,4r,4ar,6s,8as)-6-(hydroxymethyl)-4-[2-hydroxy-4-(2-methyloctan-2-yl)phenyl]-1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalen-2-ol
cp55244
cp-55,244
gtpl5568
cp55,244
79732-51-7
2-naphthalenemethanol, 8-(4-(1,1-dimethylheptyl)-2-hydroxyphenyl)decahydro- 6-hydroxy-, (2s-(2alpha,4abeta,6alpha,8alpha,8aalpha))-
(-)-cp 55244
Q27076897
DTXSID101016261
cid 9844074
rel-(2r,4ar,6s,8s,8as)-8-[4-(1,1-dimethylheptyl)-2-hydroxyphenyl]decahydro-6-hydroxy-2-naphthalenemethanol
2-naphthalenemethanol, 8-[4-(1,1-dimethylheptyl)-2-hydroxyphenyl]decahydro-6-hydroxy-, (2r,4ar,6s,8s,8as)-rel-
AKOS040748170
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1345070Human GPR55 (GPR18, GPR55 and GPR119)2011The Journal of pharmacology and experimental therapeutics, Apr, Volume: 337, Issue:1
Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (8.33)18.7374
1990's8 (66.67)18.2507
2000's2 (16.67)29.6817
2010's1 (8.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]